Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke
- 4 February 2003
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 107 (4), 598-603
- https://doi.org/10.1161/01.cir.0000046451.38849.90
Abstract
Background— Matrix metalloproteinase (MMP) expression is related to blood brain barrier disruption after cerebral ischemia. Moreover, MMP inhibitors reduce hemorrhagic transformation (HT) after embolic ischemia in tissue plasminogen activator (t-PA)–treated animals. We aimed to correlate plasmatic MMP levels with the appearance of intracranial bleeding complications in stroke patients treated with t-PA. Methods and Results— Serial MMP-2 and MMP-9 determinations were performed (ELISA, ng/mL) in 41 strokes involving the middle cerebral artery territory in patients who received t-PA within 3 hours of stroke onset. Blood samples were obtained at baseline (pretreatment) and at 12 and 24 hours after symptom onset. Hemorrhagic events were classified according to CT criteria (petechial hemorrhagic infarctions [HI, 1 to 2] and large parenchymal hemorrhages [PH, 1 to 2]). Brain CT scan was obtained at 48 hours or when a neurological worsening occurred. HT was present in 36.5% of the patients (24.4% HI and 12.1% PH). MMP-2 values were unrelated to any subtype of HT. The highest baseline MMP-9 level (normal range P =0.047). A graded response was found between mean baseline MMP-9 levels and the degree of bleeding (HI-1=37.4; HI-2=111.0; PH-1=202.5; PH-2=337.8). Baseline MMP-9 was the most powerful predictor of PH appearance in the multiple logistic regression model (OR= 9.62; CI 1.31 to 70.26; P =0.025). Conclusions— Baseline MMP-9 level predicts PH appearance after t-PA treatment. Therefore, we suggest that MMP determination may increase the safety profile for thrombolysis and, in the future, anti-MMP drugs might be combined with t-PA to prevent hemorrhagic complications.Keywords
This publication has 17 references indexed in Scilit:
- Thrombolysis-Related Hemorrhagic InfarctionStroke, 2002
- Markers of Increased Risk of Intracerebral Hemorrhage After Intravenous Recombinant Tissue Plasminogen Activator Therapy for Acute Ischemic Stroke in Clinical PracticeCirculation, 2002
- Carbohydrate source influences gelatinase production by mouse astrocytes in vitroGlia, 2002
- Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 1999
- Matrix Metalloproteinases in Cerebrovascular DiseaseJournal of Cerebral Blood Flow & Metabolism, 1998
- Hemorrhagic Transformation and Microvascular Integrity during Focal Cerebral Ischemia/ReperfusionJournal of Cerebral Blood Flow & Metabolism, 1996
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Thrombolytic Agents in the Treatment of StrokeClinical Neuropharmacology, 1990
- Metalloproteinases and their inhibitors in matrix remodelingTrends in Genetics, 1990